OpenAI announces acquisition of AI biotech startup Orchestra Bio
Founded four years ago, Orchestra Bio focused on using AI agents to help pharmaceutical companies manage tedious tasks such as clinical trial scheduling and fund tracking. The team and its technology will be integrated into OpenAI's Rosalind project, which already includes major pharma clients like Moderna and Novo Nordisk.
Return to original text
A short introduction is retained here; the full text from the source website is not reposted. For specific wording and subsequent updates, please refer to the original article.
Open the original article on ITHome